February 2009 – Click here for full issue

• Federal Circuit raises questions as to patent eligibility under § 101 of systems carrying out patent ineligible processes
• Providing information to patient on how a drug product worked did not claim patentable subject matter
• Four obviousness rulings from the Federal Circuit
• Statements made at oral hearing before BPAI held to create a disavowal of claim scope
• Use of “i.e.” in specification, rather than “e.g.” limited claim scope
• Alleged false marking of over 15,000 products was only a single offense
• Patents held unenforceable against accused infringer based on pre-suit destruction of documents